Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.51 | 0.15 | 0.03 | 0.07 |
| FCF Yield | -7.61% | -15.23% | -57.33% | -44.66% |
| EV / EBITDA | -49.83 | -20.45 | -3.70 | -2.22 |
| Quality | ||||
| ROIC | -13.25% | -18.41% | -29.46% | -52.05% |
| Gross Margin | 81.86% | 82.52% | 79.47% | 73.14% |
| Cash Conversion Ratio | 0.67 | 0.76 | 1.09 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.58% | 48.96% | 75.39% | 163.13% |
| Free Cash Flow Growth | 23.21% | 52.34% | 0.00% | -7.03% |
| Safety | ||||
| Net Debt / EBITDA | -14.28 | -6.81 | -1.10 | -0.18 |
| Interest Coverage | -1.01 | -1.65 | -5.81 | -16.04 |
| Efficiency | ||||
| Inventory Turnover | 0.76 | 0.74 | 0.92 | 0.74 |
| Cash Conversion Cycle | 527.36 | 434.80 | 426.67 | 380.46 |